Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene
- 1 September 2004
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 14 (9) , 595-605
- https://doi.org/10.1097/00008571-200409000-00004
Abstract
Carboxylesterases are members of the serine esterase super family important in the metabolism of a wide variety of substrates, including xenobiotics and prodrugs. There are two known carboxylesterases expressed in human liver, small intestine and other tissues, carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2). The aim of this study was to identify polymorphisms in the CES2 gene and determine whether these polymorphisms affect expression levels of CES2 or rate of metabolism of irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin). Microsome samples prepared from liver tissues of 78 normal individuals were used to determine the rate of hydrolysis of irinotecan and procaine (an anaesthetic hydrolysed by CES2 but not CES1). The rate of hydrolysis of irinotecan is highly variable among individuals, ranging from 2.7–138 pmol/mg protein/h (mean ± SD 26.0 ± 22.9). Fifteen single nucleotide polymorphisms (SNPs) were identified, one is in an exon, 9 are in introns, three are in the 3′-untranslated region (UTR), and two are in the 5′-flanking region. Eight of the 15 SNP loci have rare allele frequencies greater than 5%, of which three were greater than 20%. Genotyping of samples from the SNP Consortium demonstrated different distributions among African-Americans, Asian-Americans and European-Americans. We also analysed the haplotype structure and estimated linkage disequilibrium (LD). A SNP located in the 5′-UTR (5′-UTR-363) was found in LD with loci in intron 1 (Intron1 + 947, Intron1 + 1361, Intron1 + 1643). Haplotypes with homozygous rare alleles on these loci exhibit lower mRNA levels as determined by real time polymerase chain reaction (P< 0.01) and the incorporation of rare alleles in haplotypes correlate with reduced mRNA (P = 0.03). The 5′-UTR-363 SNP is located in one of the three promoters of CES2. However, we did not observe significant differences in CES2 activities (irinotecan and procaine hydrolysis) among individuals with different haplotypes.Keywords
This publication has 33 references indexed in Scilit:
- Characterization of multiple promoters in the human carboxylesterase 2 genePharmacogenetics, 2003
- Determination of Drug Interactions Occurring with the Metabolic Pathways of IrinotecanDrug Metabolism and Disposition, 2002
- Determinants of CPT-11 and SN-38 activities in human lung cancer cellsBritish Journal of Cancer, 1998
- Consed: A Graphical Tool for Sequence FinishingGenome Research, 1998
- PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencingNucleic Acids Research, 1997
- Molecular Cloning and Characterization of a Novel Putative Carboxylesterase, Present in Human Intestine and LiverBiochemical and Biophysical Research Communications, 1997
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinantsInternational Journal of Cancer, 1997
- Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.Journal of Clinical Oncology, 1996
- The metabolism of 17 alpha‐ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.British Journal of Clinical Pharmacology, 1987